Venetoclax is a specific BCL‐2 inhibitor that has been approved to treat relapsed chronic lymphocytic leukaemia (CLL)2 and shown clinical efficacy in MCL patients, especially when combined with ibrutinib.3, 4, 5. Here, BCL2 is linked to mantle cell lymphoma.